Opportunity Information: Apply for RFA HL 12 003
Apply for RFA HL 12 003
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NHLBI Translational Research Implementation Program (TRIP) Limited Competition (P50)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Oct 1, 2010 and posted on Oct 1, 2010.
- Applicants must submit their applications by Apr 4, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $13,635,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,515,000.00 in funding.
- Eligible applicants include: Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Independent school districts City or township governments For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NHLBI Translational Research Implementation Program (TRIP) Stage 2 opportunity is a National Institutes of Health funding announcement (RFA-HL-12-003) that supports specialized center grants (P50) focused on moving promising therapeutics from earlier translational work into well designed clinical trials. The core intent is practical and trial-driven: accelerate the translation of interventions that came out of fundamental discovery research by executing clinical studies that can demonstrate safety and efficacy for the treatment or prevention of cardiovascular, lung, and blood diseases. In other words, this program is aimed at bridging the gap between a compelling therapy concept and the kind of clinical evidence needed to justify broader clinical adoption or later-stage development.
This is the second step of a two-stage model. Stage 1 awards (funded previously under either RC2 or P20 mechanisms) were planning grants that enabled teams to design and prepare the clinical trials, build the infrastructure and protocols, address regulatory and operational needs, and assemble the specialized collaborations required to run strong, defensible studies. Stage 2, which is what this announcement funds, is where those planned trials are actually conducted. The FOA is explicit that Stage 2 applications should be based on the trials that were planned and developed during Stage 1 and that only those projects recommended for support following peer review move forward.
The competition is limited and not open to new entrants. Eligibility to apply is restricted to successful Stage 1 TRIP-related awardees in two groups: (1) recipients of NIH Research and Research Infrastructure Grand Opportunities (RC2) awards that were submitted in response to the NHLBI TRIP topic, and (2) recipients of NHLBI Cardiac Translational Research Implementation Program (C-TRIP) P20 awards. While the general list of eligible applicant organization types is broad (including public and private universities, nonprofits, small businesses, state and local governments, tribal entities, and certain community-based or faith-based organizations, among others), the practical gatekeeper is prior Stage 1 award status tied to TRIP or C-TRIP. This structure is meant to ensure that Stage 2 funds go to teams that have already completed rigorous planning work and are positioned to immediately implement the trials.
Funding is substantial and structured for multi-year execution. NHLBI anticipated committing approximately $13,635,000 per year to support up to six awards, each lasting up to five years. The projected budget cap for each award is up to $1,515,000 in direct costs per year, and there is no cost sharing or matching requirement stated. Because the mechanism is a P50 Specialized Center grant, the expectation is typically a coordinated, center-style effort that integrates the leadership, clinical operations, and supporting resources needed to carry out complex translational clinical research efficiently and consistently across the funded period.
In terms of research scope, the FOA is aligned with NHLBI mission areas and is categorized under CFDA numbers 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), and 93.839 (Blood Diseases and Resources Research). That indicates the program is not limited to one disease type but instead spans heart, lung, and blood conditions, as long as the proposed work is centered on testing therapeutic interventions in clinical trials with a clear path to demonstrating safety and efficacy. The underlying emphasis is on interventions that are sufficiently mature, based on prior discovery and translational groundwork, to justify rigorous clinical evaluation rather than exploratory or purely mechanistic studies.
Key administrative details include a posted date of October 1, 2010, and an application closing date of April 4, 2011 (the announcement is now archived, with an archive date of May 5, 2011). The sponsoring agency is NIH, specifically NHLBI, and the award type is a discretionary grant. The full announcement was made available through the NIH Grants Guide and includes standard NIH support resources, including contact points for technical access issues via the NIH Office of Extramural Research webmaster.
FAQs: NHLBI Translational Research Implementation Program (TRIP) Stage 2 (RFA-HL-12-003)
What is the TRIP Stage 2 funding opportunity (RFA-HL-12-003)?
TRIP Stage 2 is a National Institutes of Health (NIH) funding announcement sponsored by the National Heart, Lung, and Blood Institute (NHLBI). It supports P50 Specialized Center grants focused on implementing well designed clinical trials that test promising therapeutics for cardiovascular, lung, and blood diseases.
What is the main goal of TRIP Stage 2?
The program is designed to accelerate translation of interventions that emerged from fundamental discovery and earlier translational work by executing clinical studies intended to demonstrate safety and efficacy for treatment or prevention of cardiovascular, lung, and blood diseases.
How is Stage 2 different from Stage 1 in the TRIP model?
Stage 1 (previously funded under RC2 or P20 mechanisms) supported planning and preparation, such as designing the clinical trials, building infrastructure, developing protocols, addressing regulatory and operational needs, and forming specialized collaborations. Stage 2 funds the actual conduct of the planned clinical trials developed during Stage 1.
Is TRIP Stage 2 open to new applicants?
No. The competition is limited and not open to new entrants. Eligibility is restricted to certain prior Stage 1 awardees connected to TRIP or C-TRIP.
Who is eligible to apply for TRIP Stage 2?
Only successful Stage 1 TRIP-related awardees in two groups may apply: (1) recipients of NIH Research and Research Infrastructure Grand Opportunities (RC2) awards submitted in response to the NHLBI TRIP topic, and (2) recipients of NHLBI Cardiac Translational Research Implementation Program (C-TRIP) P20 awards.
Does the opportunity list broad organization types as eligible applicants?
Yes. The announcement describes a broad set of eligible applicant organization types (including public and private universities, nonprofits, small businesses, state and local governments, tribal entities, and certain community-based or faith-based organizations). However, the practical eligibility requirement is prior Stage 1 award status tied to TRIP or C-TRIP.
What type of grant mechanism is used for TRIP Stage 2?
The funding mechanism is a P50 Specialized Center grant. This structure typically supports a coordinated center-style effort integrating leadership, clinical operations, and supporting resources needed to run complex translational clinical research.
What kind of research activities does TRIP Stage 2 support?
The focus is practical and trial-driven: conducting clinical trials to evaluate therapeutic interventions with the aim of generating evidence of safety and efficacy. The work is intended to bridge the gap between a compelling therapy concept and the clinical evidence needed for broader clinical adoption or later-stage development.
Does TRIP Stage 2 support exploratory or mechanistic studies?
The emphasis is on interventions that are sufficiently mature to justify rigorous clinical evaluation, rather than exploratory or purely mechanistic studies.
Which disease areas are within the scope of this opportunity?
The opportunity aligns with NHLBI mission areas and spans cardiovascular, lung, and blood diseases, as long as the work centers on testing therapeutic interventions in clinical trials with a clear path to demonstrating safety and efficacy.
What are the CFDA numbers associated with this funding opportunity?
The announcement is categorized under CFDA 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), and 93.839 (Blood Diseases and Resources Research).
How much funding did NHLBI anticipate committing to TRIP Stage 2?
NHLBI anticipated committing approximately $13,635,000 per year to support up to six awards.
How many awards were expected to be made?
The announcement anticipated up to six awards.
How long can each award last?
Each award could last up to five years.
What is the budget cap per award?
The projected budget cap is up to $1,515,000 in direct costs per year for each award.
Is cost sharing or matching required?
No cost sharing or matching requirement is stated in the provided opportunity summary.
Do Stage 2 applications need to be tied to Stage 1 planning work?
Yes. The funding announcement explicitly indicates that Stage 2 applications should be based on the trials that were planned and developed during Stage 1.
Who sponsors this funding opportunity?
The sponsoring agency is NIH, specifically the National Heart, Lung, and Blood Institute (NHLBI).
What is the award type?
The award type is a discretionary grant.
When was the funding announcement posted?
The posted date is October 1, 2010.
What was the application closing date?
The application closing date was April 4, 2011.
Is this funding announcement still active?
No. The announcement is archived, with an archive date of May 5, 2011.
Where was the full announcement made available?
The full announcement was made available through the NIH Grants Guide.
Where can applicants get help with technical access issues related to NIH support resources?
The announcement references standard NIH support resources, including contact points for technical access issues via the NIH Office of Extramural Research webmaster.
Browse more opportunities from the same category: Health
Next opportunity: Animal and Biological Material Resource Centers (P40)
Previous opportunity: National Mentoring Networks to Enhance the Clinician Investigator Workforce in Deafness and Other Communication Disorders (U24)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 12 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 12 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| NIMH Research Education Programs for HIV/AIDS Research (R25) Apply for PAR 11 002 Funding Number: PAR 11 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Domestic Violence Prevention Enhancement Leadership Through Allianc (DELTA) III Apply for CE09 90103CONT11 Funding Number: CE09 90103CONT11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Affordable Care Act (ACA) Grants for School Based Health Centers Capital (SBHCC) Program Apply for HRSA 11 127 Funding Number: HRSA 11 127 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| Epidemiolgic and Ecologic Determinants of Monkeypox in a Disease endemic Setting Apply for RFA CK 11 003 Funding Number: RFA CK 11 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| NIH Directors Early Independence Awards (DP5) Apply for RFA RM 10 019 Funding Number: RFA RM 10 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01) Apply for PAR 11 003 Funding Number: PAR 11 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R21) Apply for PAR 11 004 Funding Number: PAR 11 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Sexually Transmitted Diseases/Human Immunodeficiency Virus Prevention Training Centers Apply for CDC RFA PS11 1103 Funding Number: CDC RFA PS11 1103 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,662,737 |
| RG 10102010 Email 1 Apply for RG 10102010 EMAIL 1 Funding Number: RG 10102010 EMAIL 1 Agency: IVV Test Agency Category: Health Funding Amount: Case Dependent |
| RG 10102010 Email 3 Apply for RG 10102010 EMAIL 3 Funding Number: RG 10102010 EMAIL 3 Agency: IVV Test Agency Category: Health Funding Amount: Case Dependent |
| Utilization of a Human Lung Tissue Resource for Vascular Research (R03) Apply for RFA HL 11 032 Funding Number: RFA HL 11 032 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Occupational Safety and Health Training Project Grants (T03) Apply for PAR 10 288 Funding Number: PAR 10 288 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Tropical Medicine Research Centers (P50) Apply for RFA AI 11 001 Funding Number: RFA AI 11 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening the Ministry of Health s Capacity to Respond to the HIV/AIDS Epidemic in the Republic of Rwanda under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 91180201SUPP11 Funding Number: CDC RFA PS09 91180201SUPP11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NINDS Diversity Research Education Grants in Neuroscience (R25) Apply for PAR 11 010 Funding Number: PAR 11 010 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Strengthening Integrated Delivery of HIV/AIDS Services (SIDHAS) Apply for USAID NIGERIA 620 11 001 DRAFT Funding Number: USAID NIGERIA 620 11 001 DRAFT Agency: Nigeria USAID Abuja Category: Health Funding Amount: $225,000,000 |
| ATSDR s Partnership to Promote Localized Efforts to Reduce Environmental Exposure (APPLETREE) Program Apply for CDC RFA TS11 1101 Funding Number: CDC RFA TS11 1101 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Getting from Genes to Function in Lung Disease, NHLBI (R01) Apply for PA 11 011 Funding Number: PA 11 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Toward An Improved Understanding of HDL Function, NHLBI (R01) Apply for PA 11 012 Funding Number: PA 11 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sickle Cell Disease Inflammation, Thrombosis and Vascular Dysfunction, NHLBI (R01) Apply for PA 11 013 Funding Number: PA 11 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 12 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.